PMC8477373_01
(A, B) Skin lesions on admission.
fimmu-12-731774-g001.jpg
PMC8477373_01_fimmu-12-731774-g001.jpg
f1
The blood bullae were big, loose, and easy to break, forming the erosive surface (Figures 1A, B), and accompanied by itchy and obvious pain.
Skin pathology: (A) H&E, x200; (B) H&E, x400.
fimmu-12-731774-g002.jpg
PMC8477373_01_fimmu-12-731774-g002.jpg
f2
Histopathological findings showed epidermal hyperplasia and edema, subepidermal blister formation, numerous eosinophils in the blister, and obvious eosinophil infiltration around the superficial dermis vessels (Figures 2A, B).
IgG immunoglobulin deposits along the dermo-epidermal junction.
fimmu-12-731774-g003.jpg
PMC8477373_01_fimmu-12-731774-g003.jpg
f3
Immunofluorescence was positive for IgG (Figure 3) and C3 (Figure 4).
C3 deposits along the dermo-epidermal junction.
fimmu-12-731774-g004.jpg
PMC8477373_01_fimmu-12-731774-g004.jpg
f4
Immunofluorescence was positive for IgG (Figure 3) and C3 (Figure 4).
(A, B) Skin lesions on the 8th day after glucocorticoid treatment.
fimmu-12-731774-g005.jpg
PMC8477373_01_fimmu-12-731774-g005.jpg
f5
All the superficial erosions were scabby and most of the scabs fell off, leaving dark red pigmentation spots (Figures 5A, B).
Bullous pemphigoid reappearance after steroid tapering and continuous therapy for 5 months; skin of left hip joint.
fimmu-12-731774-g006.jpg
PMC8477373_01_fimmu-12-731774-g006.jpg
f6
So far (in July 2021), the skin lesions were not healed (Figure 6), the dose of methylprednisolone was reduced to 25 mg/day, and the monitored BP180 was in the normal range.